Allopurinol, a common gout drug may offer some protection against colorectal cancers also A commonly prescribed drug used to take care of gout may also offer some safety against colorectal cancer, according to a new study from researchers at the University of Michigan and in Israel. The analysis found that sufferers taking allopurinol for at least five years experienced a two-thirds decrease in risk from colorectal cancer How long does it take for valacyclovir to start working? . It was reported through the American Association for Cancer Study Third Annual International Meeting on Frontiers in Malignancy Prevention Study in Seattle. Allopurinol warrants further investigation in chemoprevention scientific trials of colorectal cancers, stated Gad Rennert, M.D., Ph.D., director of the CHS National Cancers Control Technion and Center Public Health Discussion board in Haifa, Israel, who led the investigation with Stephen Gruber, M.D., MPH, Ph.D.
Allos to complete merger with AMAG Pharmaceuticals Allos Therapeutics, Inc. today announced that it continues to utilize AMAG Pharmaceuticals, Inc. Towards the completion of their merger, pending stockholder acceptance and satisfaction of the other circumstances to closing explained in Allos’ definitive proxy declaration filed with the SEC on September 15, 2011. On 7 October, 2011, the publicly traded pharmaceutical company that acquired previously submitted a proposal to acquire Allos for $2.20 per share in cash and share delivered a letter to Allos withdrawing its revised proposal to acquire Allos. As a result, Allos is no longer providing information to, or engaging in discussions or negotiations with, that company with regards to the revised acquisition proposal or any additional acquisition proposal..